After two recent, huge tie-ups between Takeda and Shire and Bristol-Myers Squibb and Celgene, megamergers seem to be a biopharma trend. But Roche isn’t interested, its chairman said.
The company is “extremely cautious when it comes to any kind of megamerger,” Roche Chairman Christoph Franz told CNBC at the World Economic Forum in Davos, Switzerland. Not only are huge deals costly, money-wise, but integrating big buyouts costs time and effort that’s “deviating you, maybe from some of your core activities, like, for example, research and development,” Franz told the network.
“That’s the reason why we are focusing on targeted ideas, outside our company, and then creating partnerships,” Franz said, adding that in some cases Roche would do some small- or medium-sized deals.
Franz’s comments come after this month’s $74 billion merger announcement between Bristol-Myers Squibb and Celgene, which ranks among pharma’s largest-ever deals. Also this month, Takeda closed its $62 billion buyout of Shire.
Some industry watchers questioned the motives behind those deals, and insiders at Takeda pushed back against its own proposed buyout. But while the long-term results of those acquisitions remain to be seen, Franz said his company isn’t in a position where it needs to scoop up another large pharma.
“We are benefiting from one of the best innovative pipelines, with new medicines upcoming, so there is no need to focus on acquisitions to create size,” he told CNBC.
It’s a position shared by Pfizer’s new CEO Albert Bourla, who once again swore off a megadeal during his conversation at the J.P. Morgan Healthcare Conference in San Francisco. Asked by JPMorgan analyst Chris Schott about M&A, Bourla said the company has a “unique window of opportunity to get it right with our pipeline and the new launches,” and that he doesn’t want to do a “distractive” deal.
While some top pharma execs plan to stay away from megamergers, that doesn’t mean M&A will slow entirely. Even after Bristol’s megadeal, Eli Lilly struck an $8 billion buyout of cancer specialist Loxo Oncology in early January. And GlaxoSmithKline just closed its $5 billion deal for cancer drugmaker Tesaro.
Market watchers expected an M&A boom in 2018 after U.S. tax reform, but smaller companies’ share prices—and hence valuations—remained high, putting a drag on M&A activity. Now, with lower valuations, a “pent-up demand” for buyouts and other factors, Michael Levesque, senior vice president at Moody’s, previously told FiercePharma he believes there will be an uptick of M&A this year.
By Eric Sagonowsky
Source: Fierce Pharma
This year has already witnessed a handful of memorable FDA approvals. But the race isn’t over yet. Looking to close out 2021 with FDA approvals stand four potential blockbusters from the likes of Argenx, UCB, Pfizer and Roche, according to Evaluate Pharma. Those meds combined are worth roughly $7.1 billion in sales cumulatively by 2026, according to Evaluate’s estimates.
Getting started is often the most difficult part—and that’s especially true in rare diseases and diagnoses. Patients and families often spend many years searching for their diagnosis starting point. For Horizon Therapeutics’ first innovation challenge, it took that struggle to heart and asked for technology-based rare disease solutions that result in faster or more accurate diagnoses.
Researchers from the Quadram Institute and the University of East Anglia (UEA) discovered that treating mice with broad-spectrum antibiotics increased the rate at which their breast cancer tumours grew.